[go: up one dir, main page]

AR131006A1 - Compuestos novedosos - Google Patents

Compuestos novedosos

Info

Publication number
AR131006A1
AR131006A1 ARP230103005A ARP230103005A AR131006A1 AR 131006 A1 AR131006 A1 AR 131006A1 AR P230103005 A ARP230103005 A AR P230103005A AR P230103005 A ARP230103005 A AR P230103005A AR 131006 A1 AR131006 A1 AR 131006A1
Authority
AR
Argentina
Prior art keywords
novel compounds
compounds
novel
methods
general formula
Prior art date
Application number
ARP230103005A
Other languages
English (en)
Inventor
Thomas Alexander Alanine
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Stefanie Katharina Mesch
Jonathan Martin Shannon
Andreas Michael Tosstorff
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR131006A1 publication Critical patent/AR131006A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde R¹, R², R³, R⁴ᵃ, R⁴ᵇ y R⁵ son como se describe en la presente, composición que incluye los compuestos y métodos para usar los compuestos.
ARP230103005A 2022-11-09 2023-11-08 Compuestos novedosos AR131006A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP22206280 2022-11-09

Publications (1)

Publication Number Publication Date
AR131006A1 true AR131006A1 (es) 2025-02-05

Family

ID=84330428

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230103005A AR131006A1 (es) 2022-11-09 2023-11-08 Compuestos novedosos

Country Status (6)

Country Link
EP (1) EP4615830A1 (es)
JP (1) JP2025537238A (es)
CN (1) CN120152964A (es)
AR (1) AR131006A1 (es)
TW (1) TW202428282A (es)
WO (1) WO2024099993A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
WO2025026882A1 (en) * 2023-07-28 2025-02-06 F. Hoffmann-La Roche Ag Novel compounds
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies
WO2025261430A1 (zh) * 2024-06-21 2025-12-26 成都赜灵生物医药科技有限公司 苯并噻吩类氘代化合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (es) * 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
EP4143192A1 (en) * 2020-04-30 2023-03-08 JANSSEN Pharmaceutica NV New triazinoindole compounds

Also Published As

Publication number Publication date
TW202428282A (zh) 2024-07-16
CN120152964A (zh) 2025-06-13
EP4615830A1 (en) 2025-09-17
WO2024099993A1 (en) 2024-05-16
JP2025537238A (ja) 2025-11-14

Similar Documents

Publication Publication Date Title
AR131006A1 (es) Compuestos novedosos
AR130984A1 (es) Compuestos novedosos
AR131282A1 (es) Compuestos novedosos
AR123424A1 (es) Nuevos compuestos heterocíclicos
AR131278A1 (es) Compuestos novedosos
CL2021001330A1 (es) Nuevos compuestos heterocíclicos
CL2022001091A1 (es) Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871).
CL2024004085A1 (es) Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer.
CL2023003312A1 (es) Inhibidores de nlrp3
CO2023014721A2 (es) Compuestos heterocíclicos
AR132377A1 (es) Compuestos novedosos
AR132340A1 (es) Compuestos tricíclicos para el tratamiento de cáncer
AR132456A1 (es) Compuestos novedosos
AR133266A1 (es) Macrociclos para el tratamiento de enfermedades autoinmunitarias
CL2022000019A1 (es) Nuevos compuestos heterocíclicos
CL2025000484A1 (es) Compuestos deuterados de pirimidin-2-il sulfonamida, uso para tratar trastornos desmielinizantes.
CL2025000126A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CL2025000125A1 (es) Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina.
CR20240203A (es) Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2
CL2025001640A1 (es) Inhibidores de polq
AR132992A1 (es) Agonistas de trem2
AR133375A1 (es) Compuestos novedosos
AR133076A1 (es) Compuestos novedosos
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria
AR131633A1 (es) Derivados novedosos de pirimidinil sulfonamida